Lai Wang
Insider Reports History
- Location
- Grand Cayman
- Signature
- /s/ Qing Nian, as Attorney-in-Fact
- All insider transactions
- Transactions in reports broken out by “transaction date” reported in original SEC filing, see here for transactions aggregated across transaction date
Holdings reported by Lai Wang:
| Company | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| BeOne Medicines Ltd. | President, Global Head of R&D | Ordinary Shares | 1,619,059 | $573,017,361 | $353.92 | 06 Mar 2026 | Direct |
| BeOne Medicines Ltd. | President, Global Head of R&D | Ordinary Shares | 601,965 | $213,047,452 | $353.92 | 06 Mar 2026 | Indirect |
| BeOne Medicines Ltd. | President, Global Head of R&D | American Depositary Shares | 0 | $0 | $260.00 | 23 Jun 2025 | Direct |
| BeOne Medicines Ltd. | President, Global Head of R&D | American Depositary Shares | 0 | $0 | $350.06 | 09 Sep 2025 | Indirect |
| BeOne Medicines Ltd. | President, Global Head of R&D | Share Option (Right to Buy) | 162,565 | 10 Jun 2025 | Direct | ||
| BeOne Medicines Ltd. | President, Global Head of R&D | RMB Shares | 0 | 06 Mar 2026 | Indirect |
Insider Reports Filed by Lai Wang
| Symbol | Company | Period | Transactions | Value $ | Form Type | Role | Filing Time |
|---|---|---|---|---|---|---|---|
| ONC | BeOne Medicines Ltd. | 06 Mar 2026 | 2 | $0 | 4 | President, Global Head of R&D | 10 Mar 2026, 20:13 |
| ONC | BeOne Medicines Ltd. | 31 Dec 2025 | 1 | $0 | 4 | President, Global Head of R&D | 05 Jan 2026, 17:12 |
| ONC | BeOne Medicines Ltd. | 09 Sep 2025 | 1 | -$1,750,312 | 4 | Global Head of R&D | 11 Sep 2025, 17:10 |
| ONC | BeOne Medicines Ltd. | 29 Jul 2025 | 4 | -$1,301,375 | 4 | Global Head of R&D | 31 Jul 2025, 17:05 |
| ONC | BeOne Medicines Ltd. | 18 Jul 2025 | 1 | -$210,000 | 4 | Global Head of R&D | 22 Jul 2025, 16:54 |
| ONC | BeOne Medicines Ltd. | 23 Jun 2025 | 1 | -$267,280 | 4 | Global Head of R&D | 25 Jun 2025, 17:09 |
| ONC | BeOne Medicines Ltd. | 16 Jun 2025 | 2 | -$431,699 | 4 | Global Head of R&D | 18 Jun 2025, 17:10 |
| ONC | BeOne Medicines Ltd. | 10 Jun 2025 | 2 | $0 | 4 | Global Head of R&D | 12 Jun 2025, 17:44 |
| ONC | BeOne Medicines Ltd. | 06 Jun 2025 | 4 | -$353,853 | 4 | Global Head of R&D | 10 Jun 2025, 16:56 |
| ONC | BeiGene, Ltd. | 05 Mar 2025 | 1 | $0 | 4 | Global Head of R&D | 07 Mar 2025, 19:22 |
| ONC | BeiGene, Ltd. | 21 Feb 2025 | 6 | -$1,286,174 | 4 | Global Head of R&D | 25 Feb 2025, 17:06 |
| ONC | BeiGene, Ltd. | 27 Sep 2024 | 1 | -$1,101,774 | 4 | Global Head of R&D | 01 Oct 2024, 18:29 |
| ONC | BeiGene, Ltd. | 24 Jun 2024 | 2 | -$170,030 | 4 | Global Head of R&D | 26 Jun 2024, 17:25 |
| ONC | BeiGene, Ltd. | 17 Jun 2024 | 5 | -$368,162 | 4 | Global Head of R&D | 20 Jun 2024, 17:25 |
| ONC | BeiGene, Ltd. | 05 Jun 2024 | 2 | $0 | 4 | Global Head of R&D | 07 Jun 2024, 17:03 |
| ONC | BeiGene, Ltd. | 26 Jun 2023 | 2 | -$201,567 | 4 | Global Head of R&D | 27 Jun 2023, 17:24 |
| ONC | BeiGene, Ltd. | 15 Jun 2023 | 3 | -$254,955 | 4 | Global Head of R&D | 20 Jun 2023, 18:53 |
| ONC | BeiGene, Ltd. | 07 Jun 2023 | 4 | -$103,828 | 4 | Global Head of R&D | 09 Jun 2023, 17:46 |
| ONC | BeiGene, Ltd. | 27 Jun 2022 | 1 | -$81,215 | 4 | Global Head of R&D | 28 Jun 2022, 17:32 |
| ONC | BeiGene, Ltd. | 22 Jun 2022 | 2 | $0 | 4 | Global Head of R&D | 24 Jun 2022, 17:40 |
| ONC | BeiGene, Ltd. | 17 Jun 2022 | 2 | -$169,767 | 4 | Global Head of R&D | 22 Jun 2022, 17:47 |
| ONC | BeiGene, Ltd. | 06 Jun 2022 | 1 | -$93,718 | 4 | Global Head of R&D | 08 Jun 2022, 17:43 |
| ONC | BeiGene, Ltd. | 17 May 2022 | 4 | +$4,025,737 | 4 | Global Head of R&D | 19 May 2022, 16:39 |
| ONC | BeiGene, Ltd. | 15 Dec 2021 | 4 | $0 | 4 | Global Head of R&D | 17 Dec 2021, 16:05 |
| ONC | BeiGene, Ltd. | 28 Jun 2021 | 1 | -$164,930 | 4 | Global Head of R&D | 30 Jun 2021, 16:48 |
| ONC | BeiGene, Ltd. | 16 Jun 2021 | 3 | -$265,583 | 4 | Global Head of R&D | 21 Jun 2021, 16:47 |
| ONC | BeiGene, Ltd. | 07 Jun 2021 | 1 | -$232,392 | 4 | Global Head of R&D | 09 Jun 2021, 16:46 |